Ligand Pharmaceuticals (LGND) announced the launch of Pelthos Therapeutics, a biopharmaceutical company. Pelthos is a wholly owned subsidiary of Ligand. Pelthos is committed to commercializing therapeutic products to help patients impacted by diseases with limited treatment options. The company's lead product is ZELSUVMI topical gel, 10.3%, for the treatment of molluscum contagiosum in adults and pediatric patients one year of age and older. ZELSUVMI is expected to be available in the U.S. in late 2024.
Also, Ligand Pharmaceuticals announced the appointment of Scott Plesha to the role of Chief Executive Officer. Prior to joining Pelthos, Plesha was President and Chief Commercial Officer at BioDelivery Sciences until it was acquired by Collegium Pharmaceutical in 2022.
For More Such Health News, visit rttnews.com.
For comments and feedback contact: editorial@rttnews.com
Business News
June 12, 2026 17:14 ET Major central bank action was the focus this week in economic news. The European Central Bank became the first major central bank to move in response to the rising inflationary pressures in the backdrop of the conflict in the Middle East. In North America, the U.S. inflation and trade data as well as Canada’s central bank decision gained attention. The Chinese trade data was the main news in Asia.